KP1077 Demonstrates Safety in Idiopathic Hypersomnia Patients
The phase 2 trial explored the safety and efficacy of KP1077 in reducing daytime sleepiness and sleep inertia.
Source: sleepreviewmag.com
Adrian Quartel News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Adrian Quartel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Adrian Quartel Today - Breaking & Trending Today
Zevra to Present Data from KP1077 Phase 2 Trial in IH at SLEEP
Zevra's CEO updates shareholders on recent milestones, including the completion of a phase 2 trial for idiopathic hypersomnia.
Source: sleepreviewmag.com
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript
Zevra Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.2.
Source: insidermonkey.com
Zevra Therapeutics Appoints Global Medical Leader, Adrian
CELEBRATION, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics...
Source: globenewswire.com
Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate
Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate - read this article along with other careers information, tips and advice on BioSpace
Source: biospace.com